OneAscent Financial Services LLC Has $1.92 Million Position in AbbVie Inc. $ABBV

OneAscent Financial Services LLC cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 24.2% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,280 shares of the company’s stock after selling 2,642 shares during the period. OneAscent Financial Services LLC’s holdings in AbbVie were worth $1,917,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the second quarter worth $26,000. Spurstone Advisory Services LLC purchased a new position in AbbVie in the second quarter valued at about $28,000. Financial Gravity Companies Inc. purchased a new position in AbbVie in the second quarter valued at about $36,000. Bear Mountain Capital Inc. increased its position in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares during the last quarter. Finally, Delos Wealth Advisors LLC purchased a new stake in shares of AbbVie during the 2nd quarter worth about $39,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of research reports. Bank of America increased their price objective on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Citigroup dropped their price target on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Guggenheim lifted their price objective on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. JPMorgan Chase & Co. increased their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Finally, Raymond James Financial set a $256.00 target price on AbbVie in a report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $248.11.

AbbVie Price Performance

Shares of ABBV opened at $219.21 on Monday. The company has a market capitalization of $387.42 billion, a PE ratio of 166.07, a price-to-earnings-growth ratio of 0.90 and a beta of 0.36. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company’s fifty day moving average price is $225.60 and its 200 day moving average price is $217.60.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is presently 524.24%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.